Tag: Conjugates

Over the past decades, the development and regulatory approval of antibody-based therapeutics has progressed rapidly. But poor blood-brain barrier permeability has hampered the progress...

Researchers at the Aarhus University, Denmark's second oldest university, have developed an easier method to create DNA–protein conjugates. The method can potentially strengthen the work involved in diagnosing diseases. Their findings are published in the July online edition of Nature Chemistry [1]

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) being held May 30 - June 3, 2014 in Chicago, Ill, describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Results of a randomized phase III trial evaluating the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit in...

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing a cell-free protein synthesis technology, presented the first scientific data involving...

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL offered a wealth of new...